74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Robert Redd et al.|Hematological Oncology|2025Cited by 3
289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCLAlex F. Herrera, Liangyi Chen, Sophie Buller et al.|Hematological Oncology|2025Cited by 2
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphomaVarun Iyengar, Pallawi Torka, Jomel Meeko Manzano et al.|Blood|2025Cited by 1
POSTER: ABCL-817 Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter StudyJessica Chicola, Pallawi Torka, Jomel Meeko Manzano et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
ABCL-817: Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter StudyJessica Chicola, Pallawi Torka, Jomel Meeko Manzano et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0